Homocysteine, left ventricular dysfunction and coronary artery disease: Is there a link?

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 12, 2007, Pages 1645-1651

  Rossi, Gian Paolo ^a,b   Seccia, Teresa Maria ^a   Pessina, Achille Cesare ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Cardiac dysfunction; Coronary artery disease; Homocysteine

Indexed keywords

HOMOCYSTEINE;

CARDIOVASCULAR RISK; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERTENSION; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK FACTOR; THROMBOSIS;

CORONARY ARTERY DISEASE; HEART VENTRICLES; HOMOCYSTEINE; HUMANS;

EID: 36849067969     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.353     Document Type: Conference Paper

References (46)

1. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-28.
2. Wierzbicki AS. Homocysteine and cardiovascular disease: a review of the evidence. Diab Vasc Dis Res 2007;4:143-50.
3. Kaul S, Zadeh AA, Shah PK. Homocysteine hypothesis for atherothrombotic cardiovascular disease: not validated. J Am Coll Cardiol 2006;48:914-23.
4. Rossi GP, Seccia TM, Nussdorfer GG. Reciprocal regulation of endothelin-1 and nitric oxide: relevance in the physiology and pathology of the cardiovascular system. Int Rev Cytol 2001;209:241-72.
5. Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, et al. Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005;23:233-46.
6. Paravicini TM, Touyz RM. Redox signaling in hypertension. Cardiovasc Res 2006;71:247-58.
7. Touyz RM. Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II. Curr Opin Nephrol Hypertens 2005;14:125-31.
8. Mueller CF, Laude K, McNally JS, Harrison DG. ATVB in focus: redox mechanisms in blood vessels. Arterioscler Thromb Vasc Biol 2005;25:274-8.
9. Drunat S, Moatti N, Paul JL, Cogny A, Benoit MO, Demuth K. Homocysteine-induced decrease in endothelin-1 production is initiated at the extracellular level and involves oxidative products. Eur J Biochem 2001;268:5287-94.
10. Drunat S, Moatti N, Demuth K. Homocysteine decreases endothelin-1 expression by interfering with the AP-1 signaling pathway. Free Radic Biol Med 2002;33:659-68.
11. Bleie O, Semb AG, Grundt H, Nordrehaug JE, Vollset SE, Ueland PM, et al. Homocysteine-lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease. J Intern Med 2007;262:244-53.
12. Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 2007;369:1876-82.
13. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. J Am Med Assoc 2006;296:2720-6.
14. Wald DS, Bishop L, Wald NJ, Law M, Hennessy E, Weir D, et al. Randomized trial of folic acid supplementation and serum homocysteine levels. Arch Intern Med 2001;161:695-700.
15. Wald DS, Law M, Morris J, Wald NJ. Folate and risk of cardiovascular disease. Study results were misinterpreted. Br Med J 2003;326:1035.
16. Wald DS, Wald NJ, Morris JK, Law M. Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. Br Med J 2006;333:1114-7.
17. Lonn EM, Yusuf S. Emerging approaches in the prevention of atherosclerotic cardiovascular diseases. Int J Clin Pract Suppl 1998;94:7-19.
18. B-Vitamin Treatment Trialists' Collaboration. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J 2006;151:282-7.
19. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. J Am Med Assoc 2002;288:973-9.
20. Carlsson CM, Stein JH. Clinical trials testing the homocysteine hypothesis. Ann Intern Med 2002;137:295-6.
21. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-88.
22. Spence JD. Homocysteine-lowering therapy: a role in stroke prevention? Lancet Neurol 2007;6:830-8.
23. Ambrose JA, D'Agate DJ. Plaque rupture and intracoronary thrombus in nonculprit vessels: an eyewitness account. J Am Coll Cardiol 2005;45:659-60.
24. Rossi GP, Cesari M, Zanchetta M, Colonna S, Maiolino G, Pedon L, et al. The T-786C endothelial nitric oxide synthase genotype is a novel risk factor for coronary artery disease in Caucasian patients of the GENICA study. J Am Coll Cardiol 2003;41:930-7.
25. Cesari M, Pessina AC, Zanchetta M, De Toni R, Avogaro A, Pedon L, et al. Low plasma adiponectin is associated with coronary artery disease but not with hypertension in high-risk nondiabetic patients. J Intern Med 2006;260:474-83.
26. Rossi GP, Maiolino G, Zanchetta M, Sticchi D, Pedon L, Cesari M, et al. The T(-786)C endothelial nitric oxide synthase genotype predicts cardiovascular mortality in high-risk patients. J Am Coll Cardiol 2006;48:1166-74.
27. Rossi GP, Cesari M, De Toni R, Zanchetta M, Maiolino G, Pedon L, et al. Antibodies to oxidized low-density lipoproteins and angiographically assessed coronary artery disease in white patients. Circulation 2003;108:2467-72.
28. Rossi GP, Maiolino G, Seccia TM, Burlina A, Zavattiero S, Cesari M, et al. Hyperhomocysteinemia predicts total and cardiovascular mortality in high-risk women. J Hypertens 2006;24:851-9.
29. Cesari M, Zanchetta M, Burlina A, Pedon L, Maiolino G, Sticchi D, et al. Hyperhomocysteinemia is inversely related with left ventricular ejection fraction and predicts cardiovascular mortality in high-risk coronary artery disease hypertensives. Arterioscler Thromb Vasc Biol 2005;25:115-21.
30. Cesari M, Maiolino G, Colonna S, Zanchetta M, Pedon L, Maiolino P, et al. Under treatment with lipid-lowering drugs of high-risk coronary heart disease patients of the GENICA study. J Cardiovasc Pharmacol 2003;42:484-90.
31. Kalra DK. Homocysteine and cardiovascular disease. Curr Atheroscler Rep 2004;6:101-6.
32. Durga J, Verhoef P, Bots ML, Schouten E. Homocysteine and carotid intima-media thickness: a critical appraisal of the evidence. Atherosclerosis 2004;176:1-19.
33. Furie KL, Kelly PJ. Homocyst(e)ine and stroke. Semin Neurol 2006;26:24-32.
34. Guthikonda S, Haynes WG. Homocysteine: role and implications in atherosclerosis. Curr Atheroscler Rep 2006;8:100-6.
35. Califf RM, Armstrong PW, Carver JR, D'Agostino RB, Strauss WE. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. J Am Coll Cardiol 1996;27:1007-19.
36. Mark DB, Nelson CL, Califf RM, Harrell FE Jr, Lee KL, Jones RH, et al. Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. Circulation 1994;89:2015-25.
37. Vasan RS, Beiser A, D'Agostino RB, Levy D, Selhub J, Jacques PF, et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. J Am Med Assoc 2003;289:1251-7.
38. Nasir K, Tsai M, Rosen BD, Fernandes V, Bluemke DA, Folsom AR, et al. Elevated homocysteine is associated with reduced regional left ventricular function: the Multi-Ethnic Study of Atherosclerosis. Circulation 2007;115:180-7.
39. Herrmann M, Muller S, Kindermann I, Gunther L, Konig J, Bohm M, et al. Plasma B vitamins and their relation to the severity of chronic heart failure. Am J Clin Nutr 2007;85:117-23.
40. Kennedy RH, Owings R, Shekhawat N, Joseph J. Acute negative inotropic effects of homocysteine are mediated via the endothelium. Am J Physiol Heart Circ Physiol 2004;287:H812-7.
41. Sen U, Moshal KS, Singh M, Tyagi N, Tyagi SC. Homocysteine-induced biochemical stress predisposes to cytoskeletal remodeling in stretched endothelial cells. Mol Cell Biochem 2007;302:133-43.
42. The Heart Outcomes Prevention Evaluation (HOPE). Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567-77.
43. Lange H, Suryapranata H, De Luca G, Borner C, Dille J, Kallmayer K, et al. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 2004;350:2673-81.
44. Schnyder G, Roffi M, Pin R, Flammer Y, Lange H, Eberli FR, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001;345:1593-600.
45. Herrmann W, Herrmann M, Obeid R. Hyperhomocysteinaemia: a critical review of old and new aspects. Curr Drug Metab 2007;8:17-31.
46. Loscalzo J. Homocysteine trials - clear outcomes for complex reasons. N Engl J Med 2006;354:1629-32.